Mabwell(688062)2025-02-26 08:45Financial Performance - Total revenue for 2024 reached RMB 19,878.57 million, a 55.50% increase compared to RMB 12,783.55 million in the previous year[3] - The company's net profit attributable to shareholders was RMB -106,691.89 million, with a basic earnings per share of RMB -2.67[3] - The company reported a weighted average return on equity of -51.67%, a decrease of 17.13 percentage points from -34.54% in the previous year[3] Assets and Equity - Total assets decreased by 4.45% to RMB 425,701.55 million from RMB 445,504.84 million[4] - Shareholders' equity attributable to the parent company decreased by 40.17% to RMB 154,593.85 million, with net asset value per share dropping by 40.19% to RMB 3.87[4] Revenue Drivers - The increase in revenue was primarily driven by significant sales growth of the drug Mai Li Shu® and the approval of Mai Wei Jian® in March 2024[5] Research and Development - The company maintained a high level of R&D investment as multiple innovative drugs are in critical trial stages[6] Operating Costs - Operating costs and sales expenses increased due to further market expansion and commercialization efforts[5] Financial Data Caution - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[7] - Investors are advised to be cautious due to potential investment risks associated with the preliminary financial data[7]